Search research articles
Contact Us
Filters
Showing results (131-140 of 300) with videos related to
Page
of 30
Sort By:
American Journal of Hematology
|
April 29, 2016
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
Chadi Nabhan, Xiaolei Zhou, Bann-Mo Day, et al.
Blood
|
September 11, 2004
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity
Jonathan W Friedberg, Helen Kim, Mary McCauley, et al.
Haematologica
|
July 3, 2025
Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Alexey V Danilov, Hongli Li, Mazyar Shadman, et al.
Cancer Medicine
|
October 5, 2016
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective
Robin M Reid, Andrea Baran, Jonathan W Friedberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2012
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study
Jonathan W Friedberg, Michelle Byrtek, Brian K Link, et al.
British Journal of Haematology
|
May 11, 2021
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)
Mathias J Rummel, Ann Janssens, David MacDonald, et al.
Clinical Immunology (Orlando, Fla.)
|
September 30, 2006
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
Jennifer H Anolik, Jonathan W Friedberg, Bo Zheng, et al.
Leukemia & Lymphoma
|
April 6, 2004
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison
Jonathan W Friedberg, Alan Fischman, Donna Neuberg, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 10, 2018
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
AnnaLynn M Williams, Andrea M Baran, Carla Casulo, et al.
British Journal of Haematology
|
December 18, 2019
Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma
Thomas D Rodgers, Andrea Baran, Patrick M Reagan, et al.
Page
of 30
Search research articles
Search
Showing results (131-140 of 300) with videos related to
Sort By:
Page
of 30
American Journal of Hematology
|
April 29, 2016
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
Chadi Nabhan, Xiaolei Zhou, Bann-Mo Day, et al.
Blood
|
September 11, 2004
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity
Jonathan W Friedberg, Helen Kim, Mary McCauley, et al.
Haematologica
|
July 3, 2025
Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Alexey V Danilov, Hongli Li, Mazyar Shadman, et al.
Cancer Medicine
|
October 5, 2016
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective
Robin M Reid, Andrea Baran, Jonathan W Friedberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2012
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study
Jonathan W Friedberg, Michelle Byrtek, Brian K Link, et al.
British Journal of Haematology
|
May 11, 2021
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)
Mathias J Rummel, Ann Janssens, David MacDonald, et al.
Clinical Immunology (Orlando, Fla.)
|
September 30, 2006
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
Jennifer H Anolik, Jonathan W Friedberg, Bo Zheng, et al.
Leukemia & Lymphoma
|
April 6, 2004
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison
Jonathan W Friedberg, Alan Fischman, Donna Neuberg, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 10, 2018
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
AnnaLynn M Williams, Andrea M Baran, Carla Casulo, et al.
British Journal of Haematology
|
December 18, 2019
Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma
Thomas D Rodgers, Andrea Baran, Patrick M Reagan, et al.
Page
of 30